Pelvic health impacts hundreds of millions of women globally, yet it remains one of the most under-addressed areas of healthcare. Nearly one in three women will experience a pelvic floor disorder in their lifetime, and up to 40% will develop pelvic organ prolapse. More than 50% of women experience some form of urinary incontinence. 

Despite this scale, too many patients face delayed diagnosis, limited treatment options, and care pathways that are inconvenient, invasive, or difficult to access. Many discontinue care altogether due to discomfort, stigma, or the burden of repeated in-office visits.

We started fem to modernize this entire experience. Not just with better products, but with a better system of care. One that is proactive instead of reactive. Personalized instead of one-size-fits-all. Designed for the realities of everyday life.

Pelvic health is lifelong. It changes across puberty, pregnancy, postpartum, menopause, and aging. Care should change with it.

Our vision is a world where pelvic health care is proactive, personalized, and available to every woman when she needs it.

Based in Montreal, fem has raised $4M from the world’s leading investors, including 2048 Ventures, The 51 Ventures, Mayo Clinic Platform, Montreal General Hospital Foundation, and more. fem is one of the fasted growing women’s health companies in Canada - enabling us to scale our R&D to unlock a better future in women’s health. 

femtherapeutics is built in collaboration with world-class urogynecologists from McGill University, University of Southern California, Mayo Clinic, and more. We have deep experience building medical devices and brands that have reached millions of people.